Eosinophilic rash secondary to temsirolimus

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Gandhi, Mona ^a   Kuzel, Timothy ^b   Lacouture, Mario ^a,c  

^a Department of Dermatology ^*  (United States)

^b Division of Hematology Oncology

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dermatitis; Pruritis

Indexed keywords

CLOBETASOL; INTERLEUKIN 2; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL;

AGED; ARTICLE; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL EXAMINATION; DERMATITIS; DRUG ERUPTION; EOSINOPHIL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; KNEE; LACTATE DEHYDROGENASE BLOOD LEVEL; MEDICAL EXAMINATION; SKIN BIOPSY; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

EID: 70449427402     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.019     Document Type: Article

References (13)

1. Ruiz E, Deng JS, Abell EA. Eosinophilic spongiosis: a clinical, histologic, and immunopathologic study. J Am Acad Dermatol 1994; 30:973-976
2. Ma WW, Jimeno A. Temsirolimus. Drugs Today (Barc) 2007; 43:659-669
3. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with Interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25:3958-3964
4. Coppin C, Le L, Porzsolt F, et al. Targeted therapy for advanced renal cell Carcinoma. Cochrane Database Syst Rev 2008; (2):CD006017.
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281
6. Hidalgo M, Buckner J, Erlichman C, et al. A phase 1 and pharmokinetics study of temsirolimus (CCI-779) administered intravenous daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12:5755-5763
7. Lynch T, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitorassociated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610-621
8. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144:886-892
9. Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis- Like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol 2006; 24:5786-5788
10. Kim S, Wong P, Coulombe P. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 2006; 441:362-365
11. Tracey C, Hawley C, Griffin A, et al. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl 2005; 11:987-989
12. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347
13. Bhojani N, Jeldres C, Patard J, et al. Toxicities associated with the administration of Sorafenib, sunitinib, and temsirolimus and their management in patients with Metastatic renal cell carcinoma. Eur Urol 2008; 53:917-930